Nanotechnology-based approaches for the development of diagnostics, therapeutics, and vaccines

Monoclonal Antibodies in Immunodiagnosis and Immunotherapy

Volumn 33, Issue 3, 2014, Pages 186-191

  Srinivasan, Alagarsamy ^a   Rastogi, Anshu ^a   Ayyavoo, Velpandi ^b   Srivastava, Shiv ^a  

^a Uniformed Services University of the Health Sciences and the Walter Reed National Military Medical Center   (United States)

^b UNIVERSITY OF PITTSBURGH GRADUATE SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHIMERIC PROTEIN; GAG PROTEIN; MONOCLONAL ANTIBODY; NANOPARTICLE; VACCINE; VIRUS ENVELOPE PROTEIN; VIRUS PROTEIN; VIRUS LIKE PARTICLE VACCINE;

NANOTECHNOLOGY; NONHUMAN; PHAGE DISPLAY; PRIORITY JOURNAL; RECOMBINANT DNA TECHNOLOGY; RETROVIRUS; REVIEW; VIRUS INFECTION; VIRUS LIKE AGENT; VIRUS PARTICLE; BIOSYNTHESIS; CHEMISTRY; DIAGNOSTIC USE; MOLECULAR PATHOLOGY; PROCEDURES; THERAPY;

NANOPARTICLES; NANOTECHNOLOGY; PATHOLOGY, MOLECULAR; THERAPEUTICS; VACCINES; VACCINES, VIRUS-LIKE PARTICLE;

EID: 84902650503     PISSN: None     EISSN: 21679436     Source Type: Journal    
DOI: 10.1089/mab.2014.0045     Document Type: Review

References (27)

1. Peek LJ, Middaugh CR, and Berkland C: Nanotechnology in vaccine delivery. Adv Drug Del Rev 2008;60(8):915-928. Epub 2008/03/08.
2. Jaaskelainen A, Soukka T, Lamminmaki U, Korpimaki T, and Virta M: Development of a denaturation/renaturationbased production process for ferritin nanoparticles. Biotechnol Bioeng 2009;102(4):1012-1024. Epub 2008/10/30.
3. Svenson S, and Prud'homme RK: Multifunctional Nanoparticles for Drug Delivery Applications: Imaging, Targeting, and Delivery. Springer, New York, 2012.
4. Kozlovska TM, Cielens I, Vasiljeva I, Strelnikova A, Kazaks A, Dislers A, et al: RNA phage Q beta coat protein as a carrier for foreign epitopes. Intervirology 1996;39(1-2):9-15. Epub 1996/01/01.
5. Borisova G, Borschukova Wanst O, Mezule G, Skrastina D, Petrovskis I, Dislers A, et al: Spatial structure and insertion capacity of immunodominant region of hepatitis B core antigen. Intervirology 1996;39(1-2):16-22. Epub 1996/01/01. (Pubitemid 26390692)
6. Bellier B, and Klatzmann D: Virus-like particle-based vaccines against hepatitis C virus infection. Expert Rev Vacc 2013;12(2):143-154. Epub 2013/02/19.
7. Zeltins A: Construction and characterization of virus-like particles: A review. Mol Biotechnol 2013;53(1):92-107. Epub 2012/09/25.
8. Chen Q, and Lai H: Plant-derived virus-like particles as vaccines. Hum Vacc Immunother 2013;9(1):26-49. Epub 2012/09/22.
9. Pushko P, Pumpens P, and Grens E: Development of viruslike particle technology from small highly symmetric to large complex virus-like particle structures. Intervirology 2013;56(3):141-165. Epub 2013/04/19.
10. Deml L, Speth C, Dierich MP, Wolf H, and Wagner R: Recombinant HIV-1 Pr55gag virus-like particles: Potent stimulators of innate and acquired immune responses. Mol Immunol 2005;42(2):259-277. Epub 2004/10/19. (Pubitemid 39361454)
11. Schott JW, Galla M, Godinho T, Baum C, and Schambach A: Viral and non-viral approaches for transient delivery of mRNA and proteins. Curr Gene Ther 2011;11(5):382-398. Epub 2011/07/27.
12. Dalba C, Bellier B, Kasahara N, and Klatzmann D: Replication-competent vectors and empty virus-like particles: New retroviral vector designs for cancer gene therapy or vaccines. Mol Ther 2007;15(3):457-466. Epub 2007/01/25.
13. Lai D, Singh SP, Cartas M, Murali R, Kalyanaraman VS, and Srinivasan A: Extent of incorporation of HIV-1 Vpr into the virus particles is flexible and can be modulated by expression level in cells. FEBS Lett 2000;469(2-3):191-195. Epub 2000/03/14. (Pubitemid 30129219)
14. Goff SP: Retroviridae: The retroviruses and their replication. In: Fields' Virology, 4th ed, DM Knipe (ed). Philadelphia, Lippincott Williams and Wilkins, 2001. pp. 1871-1940.
15. Freed EO, and Martin MA: HIVs and their replication. In: Fields' Virology, 4th ed, Knipe DM, (ed). Philadelphia, Lippincott Williams and Wilkins, 2001. pp. 1971-2041.
16. Bell NM, and Lever AM: HIV Gag polyprotein: Processing and early viral particle assembly. Trends Microbiol 2013;21(3):136-144. Epub 2012/12/26.
17. Lee SK, Potempa M, and Swanstrom R: The choreography of HIV-1 proteolytic processing and virion assembly. J Biol Chem 2012;287(49):40867-40874. Epub 2012/10/09.
18. Ako-Adjei D, Johnson MC, and Vogt VM: The retroviral capsid domain dictates virion size, morphology, and coassembly of gag into virus-like particles. J Virol 2005;79(21): 13463-13472. Epub 2005/10/18. (Pubitemid 41508159)
19. Gheysen D, Jacobs E, de Foresta F, Thiriart C, Francotte M, Thines D, et al: Assembly and release of HIV-1 precursor Pr55gag virus-like particles from recombinant baculovirusinfected insect cells. Cell 1989;59(1):103-112. Epub 1989/10/06. (Pubitemid 19248562)
20. Karacostas V, Nagashima K, Gonda MA, and Moss B: Human immunodeficiency virus-like particles produced by a vaccinia virus expression vector. Proc Natl Acad Sci USA 1989;86(22):8964-8967. Epub 1989/11/01. (Pubitemid 20010346)
21. Accola MA, Strack B, and Gottlinger HG: Efficient particle production by minimal Gag constructs which retain the carboxy-Terminal domain of human immunodeficiency virus type 1 capsid-p2 and a late assembly domain. J Virol 2000;74(12):5395-5402. Epub 2000/05/24. (Pubitemid 30346570)
22. Tobin GJ, Li GH, Williamson JC, Nagashima K, and Gonda MA: Synthesis and assembly of chimeric human immunodeficiency virus gag pseudovirions. Intervirology 1996;39(1-2):40-48. Epub 1996/01/01. (Pubitemid 126753548)
23. Pandey RC, Datta D, Mukerjee R, Srinivasan A, Mahalingam S, and Sawaya BE: HIV-1 Vpr: A closer look at the multifunctional protein from the structural perspective. Curr HIV Res 2009;7(2):114-128. Epub 2009/03/12.
24. Majumder B, Venkatachari NJ, Srinivasan A, and Ayyavoo V: HIV-1 mediated immune pathogenesis: Spotlight on the role of viral protein R (Vpr). Curr HIV Res 2009;7(2):169-177. Epub 2009/03/12.
25. Serio D, Rizvi TA, Cartas M, Kalyanaraman VS, Weber IT, Koprowski H, et al: Development of a novel anti-HIV-1 agent from within: Effect of chimeric Vpr-containing protease cleavage site residues on virus replication. Proc Natl Acad Sci USA 1997;94(7):3346-3351. Epub 1997/ 04/01. (Pubitemid 27157314)
26. Cartas M, Singh SP, Serio D, Rizvi TA, Kalyanaraman VS, Goldsmith CS, et al: Intravirion display of a peptide corresponding to the dimer structure of protease attenuates HIV-1 replication. DNA Cell Biol 2001;20(12):797-805. Epub 2002/03/07. (Pubitemid 34161274)
27. Liu F, Wu X, Li L, Liu Z, and Wang Z: Use of baculovirus expression system for generation of virus-like particles: Successes and challenges. Prot Express Purific 2013;90(2): 104-116. Epub 2013/06/08.